CLINICAL_TRIALS
trial_result
· 2014-07-03
Clinical Trial Update: A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma [Phase 1, Phase 2]
Summary
A Phase 1/2 study of CNTO 328 in subjects with metastatic renal cell carcinoma has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Centocor, Inc. | Conditions: Carcinoma, Renal Cell | Phase 1, Phase 2 | Status: COMPLETED